Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Paolo A. Ascierto, Grant A. McArthur, Brigitte Dréno et al. · The Lancet Oncology · 2016
Cited by 1,022 works. doi:10.1016/s1470-2045(16)30122-x
Authors
- Paolo A. Ascierto
- Grant A. McArthur
- Brigitte Dréno
- Victoria G. Atkinson
- Gabrielle Liszkay
- Anna Maria Di Giacomo
- Mario Mandalà
- Лев Вадимович Демидов
- Daniil Stroyakovskiy
- Luc Thomas
- Luis de la Cruz‐Merino
- Caroline Dutriaux
- Claus Garbe
- Yibing Yan
- Matthew J. Wongchenko
- Ilsung Chang
- Jessie J. Hsu
- Daniel O. Koralek
- Isabelle Anne Rooney
- Antoni Ribas
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
- Mutations of the BRAF gene in human cancer
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- Final Version of 2009 AJCC Melanoma Staging and Classification
- Distinct Sets of Genetic Alterations in Melanoma
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation